A Randomized, Placebo Controlled, Phase1 Study to Assess the Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects

Trial Profile

A Randomized, Placebo Controlled, Phase1 Study to Assess the Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs GMI 1271 (Primary) ; Enoxaparin sodium
  • Indications Deep vein thrombosis
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors GlycoMimetics
  • Most Recent Events

    • 24 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 08 Dec 2015 Interim results of this study (n = 18) and results of NCT02168595 study presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top